Larimar Therapeutics, Inc. (LRMR) stock forecast and price target
Price $3.02 · data as of November 13, 2026
12-month price target
Average target$14.40
Upside / downside+376.8%
Analysts10
ConsensusStrong buy
Low $5.00Average $14.40High $26.00
Gold marker: average target · white marker: today’s price ($3.02)
Analyst ratings
Strong buy 2Buy 9Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.37 | +39.6% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.06 | +22.7% | $42M |
| Quarter after ends December 31, 2026 | $-0.39 | +46.0% | $0 |
Consensus of the analysts covering Larimar Therapeutics, updated daily. In the last 30 days 6 estimates were raised and 0 lowered.
Frequently asked questions
What is the Larimar Therapeutics stock price target?
The average 12-month target from 10 analysts is $14.40, 376.8% above the current price of $3.02 Targets range from $5.00 to $26.00.
Is Larimar Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 9 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Larimar Therapeutics expected to earn?
Analysts expect EPS of $-1.37 for the fiscal year ending December 31, 2026 and $-1.06 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.